Inhibition of Irritation and Contact Hypersensitivity by Ethacrynic Acid
The immunosuppressive effect of topical ethacrynic acid (ECA) was tested on both the induction and elicitation phases of contact sensitization in a mouse model. ECA (0.5% in vehicle) reduced the sensitization response by >50% when the sensitizer was either dinitrochlorobenzene (DNCB), oxazalone (...
Gespeichert in:
| Veröffentlicht in: | Skin pharmacology and applied skin physiology 1998, Vol.11 (4-5), p.279-288 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 288 |
|---|---|
| container_issue | 4-5 |
| container_start_page | 279 |
| container_title | Skin pharmacology and applied skin physiology |
| container_volume | 11 |
| creator | Wille, John J. Kydonieus, Agis F. Kalish, Richard S. |
| description | The immunosuppressive effect of topical ethacrynic acid (ECA) was tested on both the induction and elicitation phases of contact sensitization in a mouse model. ECA (0.5% in vehicle) reduced the sensitization response by >50% when the sensitizer was either dinitrochlorobenzene (DNCB), oxazalone (OX) or para-phenylenediamine (PPD), and was applied 1 day later to the ECA-pretreated skin site. The immunosuppressive effect of combining ECA with either hydrocortisone or with cis-urocanic acid was also tested. An additive suppressive effect was observed with ECA in both combinations. The effect of ECA (1% in vehicle) on blocking the elicitation phase was also examined in a mouse ear edema assay. ECA was highly effective in preventing the challenge response in mice previously sensitized to either DNCB, OX or PPD. ECA (1% in vehicle) was also tested for its ability to inhibit contact irritation. ECA (1% in vehicle) was highly effective in preventing ear edema due to topically applied skin irritants including arachidonic acid, capsaicin, lactic acid, phorbol myristate acetate, trans-retinoic acid, and sodium lauryl sulfate. ECA may be useful for both prophylaxis and therapeutic treatment of diverse skin conditions including contact dermatitis, eczema, and other related allergic skin disorders. |
| doi_str_mv | 10.1159/000029838 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_29838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>738489261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-3143e37bce9f42dab33527d86d084b036e8cfa39d790fbe7df666c39879df87c3</originalsourceid><addsrcrecordid>eNpdkM9LwzAUx4Moc04PnkUoIoKHapO0aXIcY7rBwIueS5ofLrNLZ9IK_e-NtlTwXd57fD983-MLwCVMHiDM2GMSCjGK6RGYQkKSOMtwdjzOKD8FZ97vAkRySCZgwijNUoinYLW2W1OaxtQ2qnW0ds40_HfjVkaL2jZcNNGqOyjnlfUB_DJNF5VdtGy2XLjOGhHNhZHn4ETzyquLoc_A29PydbGKNy_P68V8E4sUoSbGMMUK56VQTKdI8hLj8J6kRCY0LRNMFBWaYyZzluhS5VITQgRmNGdS01zgGbjrfQ-u_myVb4q98UJVFbeqbn1BGMQZRTiAN__AXd06G34rEMoQZiSnAbrvIeFq753SxcGZPXddAZPiJ9pijDaw14NhW-6VHMkhy6DfDjr3glfacSuM_zOkMCUwCdhVj31w967cqPdHvgHW2YgF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225239678</pqid></control><display><type>article</type><title>Inhibition of Irritation and Contact Hypersensitivity by Ethacrynic Acid</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Wille, John J. ; Kydonieus, Agis F. ; Kalish, Richard S.</creator><creatorcontrib>Wille, John J. ; Kydonieus, Agis F. ; Kalish, Richard S.</creatorcontrib><description>The immunosuppressive effect of topical ethacrynic acid (ECA) was tested on both the induction and elicitation phases of contact sensitization in a mouse model. ECA (0.5% in vehicle) reduced the sensitization response by >50% when the sensitizer was either dinitrochlorobenzene (DNCB), oxazalone (OX) or para-phenylenediamine (PPD), and was applied 1 day later to the ECA-pretreated skin site. The immunosuppressive effect of combining ECA with either hydrocortisone or with cis-urocanic acid was also tested. An additive suppressive effect was observed with ECA in both combinations. The effect of ECA (1% in vehicle) on blocking the elicitation phase was also examined in a mouse ear edema assay. ECA was highly effective in preventing the challenge response in mice previously sensitized to either DNCB, OX or PPD. ECA (1% in vehicle) was also tested for its ability to inhibit contact irritation. ECA (1% in vehicle) was highly effective in preventing ear edema due to topically applied skin irritants including arachidonic acid, capsaicin, lactic acid, phorbol myristate acetate, trans-retinoic acid, and sodium lauryl sulfate. ECA may be useful for both prophylaxis and therapeutic treatment of diverse skin conditions including contact dermatitis, eczema, and other related allergic skin disorders.</description><identifier>ISSN: 1660-5527</identifier><identifier>ISSN: 1422-2868</identifier><identifier>EISSN: 1660-5535</identifier><identifier>EISSN: 1422-2906</identifier><identifier>DOI: 10.1159/000029838</identifier><identifier>PMID: 9885413</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Biological and medical sciences ; Dermatitis, Contact - drug therapy ; Dermatitis, Contact - pathology ; Ear, External - pathology ; Ethacrynic Acid - pharmacology ; Female ; Histamine and antagonists. Allergy ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Original Research Article ; Pharmacology. Drug treatments ; Skin, nail, hair, dermoskeleton ; Surface-Active Agents - pharmacology</subject><ispartof>Skin pharmacology and applied skin physiology, 1998, Vol.11 (4-5), p.279-288</ispartof><rights>1998 S. Karger AG, Basel</rights><rights>1999 INIST-CNRS</rights><rights>Copyright (c) 1998 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-3143e37bce9f42dab33527d86d084b036e8cfa39d790fbe7df666c39879df87c3</citedby><cites>FETCH-LOGICAL-c422t-3143e37bce9f42dab33527d86d084b036e8cfa39d790fbe7df666c39879df87c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1814610$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9885413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wille, John J.</creatorcontrib><creatorcontrib>Kydonieus, Agis F.</creatorcontrib><creatorcontrib>Kalish, Richard S.</creatorcontrib><title>Inhibition of Irritation and Contact Hypersensitivity by Ethacrynic Acid</title><title>Skin pharmacology and applied skin physiology</title><addtitle>Skin Pharmacol Physiol</addtitle><description>The immunosuppressive effect of topical ethacrynic acid (ECA) was tested on both the induction and elicitation phases of contact sensitization in a mouse model. ECA (0.5% in vehicle) reduced the sensitization response by >50% when the sensitizer was either dinitrochlorobenzene (DNCB), oxazalone (OX) or para-phenylenediamine (PPD), and was applied 1 day later to the ECA-pretreated skin site. The immunosuppressive effect of combining ECA with either hydrocortisone or with cis-urocanic acid was also tested. An additive suppressive effect was observed with ECA in both combinations. The effect of ECA (1% in vehicle) on blocking the elicitation phase was also examined in a mouse ear edema assay. ECA was highly effective in preventing the challenge response in mice previously sensitized to either DNCB, OX or PPD. ECA (1% in vehicle) was also tested for its ability to inhibit contact irritation. ECA (1% in vehicle) was highly effective in preventing ear edema due to topically applied skin irritants including arachidonic acid, capsaicin, lactic acid, phorbol myristate acetate, trans-retinoic acid, and sodium lauryl sulfate. ECA may be useful for both prophylaxis and therapeutic treatment of diverse skin conditions including contact dermatitis, eczema, and other related allergic skin disorders.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Dermatitis, Contact - drug therapy</subject><subject>Dermatitis, Contact - pathology</subject><subject>Ear, External - pathology</subject><subject>Ethacrynic Acid - pharmacology</subject><subject>Female</subject><subject>Histamine and antagonists. Allergy</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Original Research Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Skin, nail, hair, dermoskeleton</subject><subject>Surface-Active Agents - pharmacology</subject><issn>1660-5527</issn><issn>1422-2868</issn><issn>1660-5535</issn><issn>1422-2906</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkM9LwzAUx4Moc04PnkUoIoKHapO0aXIcY7rBwIueS5ofLrNLZ9IK_e-NtlTwXd57fD983-MLwCVMHiDM2GMSCjGK6RGYQkKSOMtwdjzOKD8FZ97vAkRySCZgwijNUoinYLW2W1OaxtQ2qnW0ds40_HfjVkaL2jZcNNGqOyjnlfUB_DJNF5VdtGy2XLjOGhHNhZHn4ETzyquLoc_A29PydbGKNy_P68V8E4sUoSbGMMUK56VQTKdI8hLj8J6kRCY0LRNMFBWaYyZzluhS5VITQgRmNGdS01zgGbjrfQ-u_myVb4q98UJVFbeqbn1BGMQZRTiAN__AXd06G34rEMoQZiSnAbrvIeFq753SxcGZPXddAZPiJ9pijDaw14NhW-6VHMkhy6DfDjr3glfacSuM_zOkMCUwCdhVj31w967cqPdHvgHW2YgF</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>Wille, John J.</creator><creator>Kydonieus, Agis F.</creator><creator>Kalish, Richard S.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Inhibition of Irritation and Contact Hypersensitivity by Ethacrynic Acid</title><author>Wille, John J. ; Kydonieus, Agis F. ; Kalish, Richard S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-3143e37bce9f42dab33527d86d084b036e8cfa39d790fbe7df666c39879df87c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Dermatitis, Contact - drug therapy</topic><topic>Dermatitis, Contact - pathology</topic><topic>Ear, External - pathology</topic><topic>Ethacrynic Acid - pharmacology</topic><topic>Female</topic><topic>Histamine and antagonists. Allergy</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Original Research Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Skin, nail, hair, dermoskeleton</topic><topic>Surface-Active Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wille, John J.</creatorcontrib><creatorcontrib>Kydonieus, Agis F.</creatorcontrib><creatorcontrib>Kalish, Richard S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Skin pharmacology and applied skin physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wille, John J.</au><au>Kydonieus, Agis F.</au><au>Kalish, Richard S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of Irritation and Contact Hypersensitivity by Ethacrynic Acid</atitle><jtitle>Skin pharmacology and applied skin physiology</jtitle><addtitle>Skin Pharmacol Physiol</addtitle><date>1998</date><risdate>1998</risdate><volume>11</volume><issue>4-5</issue><spage>279</spage><epage>288</epage><pages>279-288</pages><issn>1660-5527</issn><issn>1422-2868</issn><eissn>1660-5535</eissn><eissn>1422-2906</eissn><abstract>The immunosuppressive effect of topical ethacrynic acid (ECA) was tested on both the induction and elicitation phases of contact sensitization in a mouse model. ECA (0.5% in vehicle) reduced the sensitization response by >50% when the sensitizer was either dinitrochlorobenzene (DNCB), oxazalone (OX) or para-phenylenediamine (PPD), and was applied 1 day later to the ECA-pretreated skin site. The immunosuppressive effect of combining ECA with either hydrocortisone or with cis-urocanic acid was also tested. An additive suppressive effect was observed with ECA in both combinations. The effect of ECA (1% in vehicle) on blocking the elicitation phase was also examined in a mouse ear edema assay. ECA was highly effective in preventing the challenge response in mice previously sensitized to either DNCB, OX or PPD. ECA (1% in vehicle) was also tested for its ability to inhibit contact irritation. ECA (1% in vehicle) was highly effective in preventing ear edema due to topically applied skin irritants including arachidonic acid, capsaicin, lactic acid, phorbol myristate acetate, trans-retinoic acid, and sodium lauryl sulfate. ECA may be useful for both prophylaxis and therapeutic treatment of diverse skin conditions including contact dermatitis, eczema, and other related allergic skin disorders.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>9885413</pmid><doi>10.1159/000029838</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1660-5527 |
| ispartof | Skin pharmacology and applied skin physiology, 1998, Vol.11 (4-5), p.279-288 |
| issn | 1660-5527 1422-2868 1660-5535 1422-2906 |
| language | eng |
| recordid | cdi_karger_primary_29838 |
| source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
| subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - pharmacology Biological and medical sciences Dermatitis, Contact - drug therapy Dermatitis, Contact - pathology Ear, External - pathology Ethacrynic Acid - pharmacology Female Histamine and antagonists. Allergy Medical sciences Mice Mice, Inbred BALB C Original Research Article Pharmacology. Drug treatments Skin, nail, hair, dermoskeleton Surface-Active Agents - pharmacology |
| title | Inhibition of Irritation and Contact Hypersensitivity by Ethacrynic Acid |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20Irritation%20and%20Contact%20Hypersensitivity%20by%20Ethacrynic%20Acid&rft.jtitle=Skin%20pharmacology%20and%20applied%20skin%20physiology&rft.au=Wille,%20John%20J.&rft.date=1998&rft.volume=11&rft.issue=4-5&rft.spage=279&rft.epage=288&rft.pages=279-288&rft.issn=1660-5527&rft.eissn=1660-5535&rft_id=info:doi/10.1159/000029838&rft_dat=%3Cproquest_karge%3E738489261%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225239678&rft_id=info:pmid/9885413&rfr_iscdi=true |